Oro-mandibular dystonia developing with both sertraline and fluoxetine use in a female adolescent with major depressive disorder
dc.authorid | 0000-0002-4284-9411 | en_US |
dc.authorid | 0000-0001-5207-6240 | en_US |
dc.authorid | 0000-0002-3412-9879 | en_US |
dc.authorid | 0000-0002-8980-6072 | en_US |
dc.contributor.author | Sarıoğlu, Setenay | |
dc.contributor.author | Tufan, Ali Evren | |
dc.contributor.author | Öztürk, Yusuf | |
dc.contributor.author | Özdemir, Dilara | |
dc.date.accessioned | 2023-11-20T08:25:15Z | |
dc.date.available | 2023-11-20T08:25:15Z | |
dc.date.issued | 2022 | en_US |
dc.department | BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.description.abstract | Oro-mandibular dystonia (OMD) involves repetitive uncontrollable contractions of the lower facial muscles (Scorr et al. 2021). Its etiology is not fully elucidated although various neurological (encephalitis, etc.), psychogenic and psychopharmacological (SSRIs, antipsychotics etc.) causes were implicated (Kutuk et al. 2019, Scorr et al. 2021). The odds ratio (OR) is 1.7 for dystonia in general after using SSRIs (Revet et al. 2020). Paroxetine (OR= 1.7) and fluoxetine (OR= 1.5) have the highest risks among SSRIs while escitalopram has the lowest (OR=0.8, Revet et al. 2020). Adolescent patients developing OMD after treatment with sertraline or fluoxetine alone were reported previously (Kutuk et al. 2019, Revet et al. 2020). However, OMD in a patient with sequential trials of different SSRIs are not reported up to now. | en_US |
dc.identifier.citation | Sarioglu, S., Ali, E. T., Ozturk, Y., & Ozdemir, D. (2022). Oro-Mandibular Dystonia Developing with both Sertraline and Fluoxetine Use in a Female Adolescent with Major Depressive Disorder. Psychiatry and Behavioral Sciences, 12(4), 210. | en_US |
dc.identifier.doi | 10.5455/PBS.20221012042348 | |
dc.identifier.endpage | 211 | en_US |
dc.identifier.issn | 2636-834X | |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 210 | en_US |
dc.identifier.uri | http://dx.doi.org/10.5455/PBS.20221012042348 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12491/11858 | |
dc.identifier.volume | 12 | en_US |
dc.identifier.wos | WOS:000906767600007 | en_US |
dc.identifier.wosquality | N/A | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.institutionauthor | Sarıoğlu, Setenay | |
dc.institutionauthor | Tufan, Ali Evren | |
dc.institutionauthor | Öztürk, Yusuf | |
dc.institutionauthor | Özdemir, Dilara | |
dc.language.iso | en | en_US |
dc.publisher | Yerküre Tanıtım ve Yayıncılık Hizmetleri A.Ş. | en_US |
dc.relation.ispartof | Psychiatry and Behavioral Sciences | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Oro-Mandibular Dystonia | en_US |
dc.subject | Fluoxetine | en_US |
dc.subject | Sertraline | en_US |
dc.subject | Major Depressive Disorder | en_US |
dc.title | Oro-mandibular dystonia developing with both sertraline and fluoxetine use in a female adolescent with major depressive disorder | en_US |
dc.type | Article | en_US |